- Home
- BLND vs OCS Comparison
BLND vs OCS Comparison
Compare BLND & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLND
- OCS
- Stock Information
- Founded
- BLND 2012
- OCS 2003
- Country
- BLND United States
- OCS Switzerland
- Employees
- BLND N/A
- OCS N/A
- Industry
- BLND EDP Services
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- BLND Technology
- OCS Health Care
- Exchange
- BLND Nasdaq
- OCS Nasdaq
- Market Cap
- BLND 925.5M
- OCS 1.0B
- IPO Year
- BLND 2021
- OCS N/A
- Fundamental
- Price
- BLND $3.45
- OCS $18.99
- Analyst Decision
- BLND Buy
- OCS Strong Buy
- Analyst Count
- BLND 7
- OCS 3
- Target Price
- BLND $4.93
- OCS $35.33
- AVG Volume (30 Days)
- BLND 1.9M
- OCS 27.9K
- Earning Date
- BLND 08-07-2025
- OCS 08-26-2025
- Dividend Yield
- BLND N/A
- OCS N/A
- EPS Growth
- BLND N/A
- OCS N/A
- EPS
- BLND N/A
- OCS N/A
- Revenue
- BLND $164,949,000.00
- OCS $847,333.00
- Revenue This Year
- BLND N/A
- OCS $18.70
- Revenue Next Year
- BLND $28.57
- OCS $1,059.78
- P/E Ratio
- BLND N/A
- OCS N/A
- Revenue Growth
- BLND 15.07
- OCS N/A
- 52 Week Low
- BLND $2.27
- OCS $10.79
- 52 Week High
- BLND $5.53
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- BLND 47.78
- OCS 50.02
- Support Level
- BLND $3.17
- OCS $19.11
- Resistance Level
- BLND $3.37
- OCS $19.75
- Average True Range (ATR)
- BLND 0.14
- OCS 0.42
- MACD
- BLND -0.01
- OCS -0.08
- Stochastic Oscillator
- BLND 42.05
- OCS 45.59
About BLND Blend Labs Inc.
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segments are; Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience, and the Title segment enables customers to streamline the title, settlement, and closing process at scale for mortgages, home equity lines of credit, and home equity loans. The majority of the revenue for the company is generated from the Blend Platform segment.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.